Company Encyclopedia
View More
name
DarioHealth
DRIO.US
DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Connect, a solution used to create communities around specific health conditions to increase awareness and education; Dario Mind, a behavioral health offering that decreases the symptoms of stress, anxiety, and depression; Dario Move, focuses on improving posture to alleviate pain with medical device; and Dario Health, a self-care application and virtual coaching platform for diabetes, hypertension, and weight management and GLP-1.
70.40 B
DRIO.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care TechnologyIndustry
Industry Ranking19/44
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-50.95%E
    • Profit Margin-171.09%E
    • Gross Margin63.83%A
  • Growth ScoreC
    • Revenue YoY7.29%B
    • Net Profit YoY-5.25%C
    • Total Assets YoY7.07%B
    • Net Assets YoY28.07%A
  • Cash ScoreC
    • Cash Flow Margin-72.75%D
    • OCF YoY7.29%B
  • Operating ScoreD
    • Turnover0.22D
  • Debt ScoreB
    • Gearing Ratio36.35%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    DarioHealth Signs 79 New Employer Clients in 2025

    DarioHealth Corp. announced it has signed 79 new employer clients in 2025, surpassing its target of 40. The new agreements will contribute to revenue in Q1 2026, with most clients addressing cardiometabolic conditions. The company continues to grow among self-insured employers seeking digital health solutions.

    Reuters·
    US
    DRIO
    +1.69%
    Reuters·
    US
    DRIO
    +1.69%

    DarioHealth Digital Platform Cuts Hospitalization Rates and Healthcare Costs, Peer-Reviewed Study Finds

    DarioHealth Corp.'s digital health platform for Type 2 Diabetes patients significantly reduces hospitalization rates by 23% and medical costs by 26%, saving $5,077 annually per user, according to a peer-reviewed study published in the Journal of Medical Internet Research. The study highlights the benefits of frequent engagement with the platform, leading to fewer inpatient and emergency room visits.

    Reuters·
    US
    DRIO
    +1.69%
    Reuters·
    US
    DRIO
    +1.69%

    Stifel Nicolaus Remains a Buy on DarioHealth (DRIO)

    Stifel Nicolaus analyst David Grossman maintains a Buy rating on DarioHealth with a $16.00 price target. Grossman, a 4-star analyst, has a 7.9% average return and a 54.07% success rate. The general consensus on The Street is a Moderate Buy for DarioHealth with a $13.50 average price target.

    Tip Ranks·
    US
    DRIO
    +1.69%
    Tip Ranks·
    US
    DRIO
    +1.69%

    DarioHealth Reports Q3 2025 Financial Results

    DarioHealth reported Q3 2025 financial results with a revenue decrease to $5.007 million from $7.423 million year-over-year. The net loss improved to $10.466 million from $12.330 million. Operating expenses reduced to $12.499 million from $15.907 million, showing efforts to streamline operations. Despite challenges, the company focuses on expanding digital therapeutic solutions and aims for sustainable growth.

    Tip Ranks·
    US
    DRIO
    +1.69%
    Tip Ranks·
    US
    DRIO
    +1.69%

    DarioHealth misses Q3 revenue estimates

    DarioHealth's Q3 2025 revenue fell short of analyst expectations, though net income exceeded forecasts. The company aims for $12.4 million in new business for 2025 and expects cashflow breakeven by late 2026 to early 2027. Revenue decline was due to a shift to a high-margin recurring revenue model. Operating expenses dropped by 31% in the first nine months of 2025. Analysts rate the stock as a "buy" with a median price target of $25.00, 53% above its current price.

    Reuters·
    US
    DRIO
    +1.69%
    Reuters·
    US
    DRIO
    +1.69%
    © 2025 Longbridge｜Disclaimer